Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer

2013 ASCO Annual Meeting

30 May - 3 Jun 2013

Published: 3 Jun 2013

Views: 4841

Rating:

Save

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA

Dr Suresh S. Ramalingam presents data on a large randomised phase II study, GALAXY-1, during a press conference at the 2013 ASCO Annual Meeting.

The study found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line (salvage) therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma that progresses after initial therapy. If confirmed in an ongoing phase III trial, this would be the first treatment to improve patient outcomes in this setting in a decade.

Visit ecancerNews to read more

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer

Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer ( Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel )

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

More from ecancer